GlassScriptPhysician profile
Jack L Cortese
NPI 1659374577
$11,400.47
in general payments reported to CMS, 2019-2025
33 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $2,475 · 2021: $1,520 · 2022: $1,757 · 2023: $2,504 · 2024: $1,479 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,054 · Education: $25.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,054.32 |
| Education | $25.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,717.45 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $1,108.78 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $865.03 | 2019-2025 | Farxiga, Lokelma |
| Outset Medical INC | $583.48 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $548.67 | 2022-2025 | Tarpeyo |
| Nuwellis, INC. | $544.52 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $509.44 | 2022-2024 | Lupkynis |
| Vifor Pharma, INC. | $504.10 | 2019-2025 | Veltassa |
| Amgen INC. | $480.73 | 2021-2025 | Tavneos, Krystexxa |
| Corcept Therapeutics | $307.21 | 2023-2025 | Korlym |
| Mallinckrodt Hospital Products INC. | $270.39 | 2021-2025 | Terlivaz |
| Actelion Pharmaceuticals US, INC. | $267.40 | 2022-2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.22 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $205.22 | 2022-2023 | Bexsero, Benlysta, Jesduvroq |
| Abbott Laboratories | $180.26 | 2021-2024 | Cardiomems |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $127.08 | 2021 | |
| Travere Therapeutics, INC. | $109.53 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $109.03 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $105.38 | 2019 | |
| Csl Behring | $94.83 | 2020-2021 | |
| Akebia Therapeutics INC | $85.47 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $81.27 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $69.17 | 2025 | Recorlev |
| Ardelyx, INC. | $59.23 | 2023-2024 | Ibsrela |
| Nevro Corp. | $40.62 | 2022 | |
| Fresenius USA Marketing, INC. | $30.59 | 2019-2021 | |
| Baxter Healthcare | $25.60 | 2020 | |
| Scpharmaceuticals INC. | $24.00 | 2025 | |
| Novo Nordisk INC | $23.67 | 2023 | Wegovy |
| Melinta Therapeutics, LLC | $21.78 | 2023 | Kimyrsa |
| Lilly USA, LLC | $20.95 | 2023 | Mounjaro |
| Ani Pharmaceuticals, INC. | $20.20 | 2024 | Purified Cortrophin Gel |
| Shield Therapeutics INC | $13.17 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Cortese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.